OncLive SOSS

Latest Conference Articles

The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.

Atezolizumab Plus Bevacizumab Shows Encouraging Clinical Activity in mRCC

September 11th 2017, 4:55pm

Atezolizumab with bevacizumab provided improved progression-free survival over sunitinib in patients with untreated metastatic renal cell carcinoma.

Frontline Dabrafenib/Trametinib Effective for BRAF+ NSCLC

September 11th 2017, 3:59pm

Frontline treatment with the combination of dabrafenib and trametinib showed promising clinical efficacy for patients with BRAF-mutant metastatic non–small cell lung cancer.

Adjuvant Dabrafenib/Trametinib Doubles RFS for BRAF+ Melanoma

September 11th 2017, 11:17am

Adjuvant treatment with dabrafenib and trametinib reduced the risk of relapse or death by 53% compared with placebo for patients with stage III BRAF-mutant melanoma.

Pembrolizumab Shows Greater Long-Term Benefits Versus Chemo for Urothelial Carcinoma

September 10th 2017, 10:20pm

Mature results from the phase III KEYNOTE-045 study presented at the 2017 ESMO Congress demonstrated that overall survival with pembrolizumab (Keytruda) continued to improve compared to chemotherapy in patients with recurrent, advanced urothelial carcinoma.

Dr. Mirza on Niraparib Plus Bevacizumab Combo in Ovarian Cancer

September 10th 2017, 9:52pm

Mansoor Raza Mirza, MD, chief oncologist in the Department of Oncology in Rigshospitalet, Copenhagen University Hospital, Denmark, and medical director of the Nordic Society of Gynecologic Oncology-Clinical Trial Unit, discusses phase I results of a trial exploring the combination of niraparib (Zejula) and bevacizumab (Avastin) in patients with platinum-sensitive epithelial ovarian cancer.

Dr. Choueiri on Impact of CABOSUN Results in Renal Cell Carcinoma

September 10th 2017, 9:05pm

Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the significance of the phase II CABOSUN trial, which explored cabozantinib (Cabometyx) as a frontline therapy for patients with renal cell carcinoma (RCC).

Enhanced Post-Surgery Surveillance Not Linked to Longer OS in NSCLC

September 10th 2017, 8:36pm

Expanding surveillance after surgery for early-stage non–small cell lung cancer from chest x-ray to follow-up with PET-CT scan did not improve overall survival.

PD-1/IDO Combination Active in Advanced Melanoma

September 10th 2017, 6:04pm

A majority of patients with advanced melanoma responded to the combination of pembrolizumab and the investigational IDO1 inhibitor epacadostat.

Abemaciclib Improves PFS for HR+/HER2- Advanced Breast Cancer

September 10th 2017, 10:37am

The addition of abemaciclib to anastrozole or letrozole reduced the risk of progression or death by 46% compared with the non-steroidal aromatase inhibitors alone for previously untreated patients with HER2-negative, HR-positive advanced breast cancer.

Denosumab May Help Some With Bone Tumors Avoid Surgery

September 9th 2017, 10:21pm

More than one-third of patients with resectable giant cell tumor of bone avoided surgery and nearly half had less morbidity with surgery when treated with denosumab (Xgeva).

Nab-Paclitaxel Alone and With Durvalumab Shows Promise in NSCLC

September 9th 2017, 8:58pm

Nab-paclitaxel (Abraxane) monotherapy has efficacy in patients with pretreated advanced nonsquamous non-small cell lung cancer that is not improved by the addition of CC-486.

Immune System Priming Prior to Checkpoint Blockade Improves Response in Metastatic TNBC

September 9th 2017, 8:58pm

Turning a nonimmunogenic (“cold”) tumor into an immunogenic (“hot”) tumor appears feasible in patients with metastatic triple negative breast cancer, thereby improving sensitivity to immune therapy with nivolumab.

Binimetinib Adds to Encorafenib PFS Benefit for BRAF+ Melanoma

September 9th 2017, 8:01pm

The combination of encorafenib and binimetinib demonstrated significant improvements in PFS compared with single-agent vemurafenib or encorafenib for patients with BRAF-mutant advanced melanoma.

Dr. Palmerini on Long-term Efficacy of Denosumab in Giant Cell Tumor of Bone

September 9th 2017, 7:54pm

Emanuela Palmerini, MD, Prometeo Laboratory: Clinical and Experimental Research Contract, Chemotherapy for Rare Musculoskeletal Tumors Department, Rizzoli Orthopaedic Institute, discusses the long-term efficacy of denosumab (Xgeva) in patients with giant cell tumor of bone.

Dr. Ledermann on Phase III ARIEL3 Results in Ovarian Cancer

September 9th 2017, 7:43pm

Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, United Kingdom, discusses the phase III results of the ARIEL3 trial in ovarian cancer during the 2017 ESMO Congress.

Liquid Biopsy for Mutation Burden Predicts PFS in NSCLC Immunotherapy

September 9th 2017, 6:45pm

A liquid biopsy that measures tumor mutational burden showed promise as an aid for predicting benefit in patients with non-small cell lung cancer treated with a checkpoint inhibitor.

Nivolumab Past One Year Improves Progression-Free Survival in Pretreated NSCLC

September 9th 2017, 6:00pm

Continuous treatment with nivolumab until disease progression was associated with superior progression-free survival compared with a 1-year fixed duration treatment for patients with previously treated advanced non-small cell lung cancer.

Durvalumab "Game-Changer" for Locally Advanced Lung Cancer

September 9th 2017, 10:42am

The PD-L1 inhibitor durvalumab improved median progression-free survival by 11.2 months compared with placebo for patients with locally advanced, unresectable stage III lung cancer who had not progressed following chemoradiotherapy.

Frontline Osimertinib Doubles PFS for EGFR+ NSCLC

September 9th 2017, 10:26am

Frontline osimertinib improved median progression-free survival by 18.9 months, representing a 54% reduction in the risk of progression or death compared with standard therapy for patients with EGFR-mutant non–small cell lung caner.

Taselisib, Letrozole Combination Active for ER+, HER2- Early Breast Cancer

September 8th 2017, 9:00pm

Taselisib added to standard letrozole (Femara) improved the objective response rate compared to letrozole with a placebo in postmenopausal women with estrogen receptor-positive and HER2-negative early breast cancer.